



STATE OF MICHIGAN

GRETCHEN WHITMER
GOVERNOR

DEPARTMENT OF HEALTH AND HUMAN SERVICES
LANSING

ELIZABETH HERTEL
DIRECTOR

Standing Order Information Packet-Naloxone Prescription for Opioid Overdose Prevention

I. OVERVIEW

Naloxone hydrochloride (naloxone) is a medication intended for reversal of an overdose that is the result of consumption or use of one or more opioids or opioid-related substances. This includes morphine, heroin, oxycodone, hydromorphone, and synthetic analogues such as fentanyl and carfentanil. Naloxone will not reverse drug overdoses related to non-opioid substances.

The Chief Medical Executive (CME) does not provide prior authorizations under this standing order. Persons, pharmacists, and insurance companies should work directly with the individuals primary care provider to obtain any prior authorization.

II. PURPOSE

This standing order is intended to ensure that individuals within the State of Michigan who are at risk of experiencing an opioid overdose, or who are family members, friends or other persons who are able to assist a person at risk of experiencing an opioid-related overdose (henceforth referred to as "Eligible Individuals"), are able to obtain naloxone. This order is not intended to be used by organizations that employ or contract with a prescriber who is authorized to write prescriptions. Such organizations should utilize the medical professionals with whom they have a relationship to write prescriptions specific to personnel who would be expected to administer naloxone.

III. AUTHORITY

This standing order is issued pursuant to Michigan law which allows the CME to issue a standing order that does not identify particular persons at the time it is issued, for the purpose of a pharmacist, community-based organization, or a staff member of the community-based organization dispensing the opioid antagonist naloxone. MCL 333.17701 *et seq.*, ([click here for Standing Order provisions](#)).

IV. AUTHORIZATION

This standing order may be used by pharmacists to generate a prescription for Eligible Individuals to obtain naloxone from a pharmacy. This order is authorization for pharmacists to dispense naloxone and devices for administration SOLELY of the FDA-approved naloxone formulations and devices prescribed herein. This standing order is intended to cover all formulations of naloxone and is not limited to any particular brand. A pharmacist may dispense naloxone irrespective of whether a formulation is available without a prescription (i.e. available over the counter).

Pharmacists and community-based organizations (CBOs) may operate under this standing order to distribute naloxone to eligible individuals directly or through indirect means (i.e. non-staffed distribution mechanisms), if the educational material is provided to eligible individuals as directed below.

“Eligible Individuals.” as defined in Michigan Administrative R. 338.201(c), means “individuals within the State of Michigan who are seeking opioid antagonists.”

“Community-Based Organization.” as defined in MCL 333.17744e(5), means “a public or private organization that provides health or human services to meet the needs of a community, including, but not limited to, a nonprofit organization, a social service provider, or an organization providing substance use disorder prevention, treatment, recovery, or harm reduction services.”

V. INSTRUCTIONAL MATERIALS FOR ELIGIBLE INDIVIDUALS- USE OF NALOXONE
Under the related administrative rules, pharmacists will be required to follow the Standing Order stipulations as outlined.

A. TRAINING

It is required that prescribers and dispensers of naloxone are appropriately trained in its administration and will educate individual recipients of naloxone.

B. PROVISION OF EDUCATIONAL MATERIALS WITH EACH PRESCRIPTION OR DRUG

It is recommended that pharmacies and CBOs advertise the availability of naloxone at their locations through visible postings. Prior to dispensing naloxone under this standing order, pharmacists shall advise Eligible Individuals to review educational materials approved by the Michigan Department of Health and Human Services (MDHHS) found online at the MDHHS website: michigan.gov/opioids

This information includes guidance for calling 911 when naloxone is administered.

Pharmacists dispensing naloxone under this standing order must provide information on the best formulation (dose and route) to be used in various settings, in order to most effectively minimize the risk of overdose death while balancing the potential of withdrawal symptoms.

CBOs distributing naloxone under this standing order must make available to Eligible Individuals educational materials found online at the MDHHS website: michigan.gov/opioids

C. APPROPRIATE USE AND DIRECTIONS FOR FDA-APPROVED NALOXONE

Eligible Individuals should be aware of information specific to the drug that is dispensed to them when interacting with a person who is suspected of experiencing an opioid overdose event.

VI. INSTRUCTIONAL MATERIALS FOR ELIGIBLE INDIVIDUALS -ADDITIONAL INFORMATION MAY BE FOUND HERE: <https://www.michigan.gov/opioids/find-help/naloxone-page>

VII. COUNSELING: REFERRAL AND/OR FOLLOW-UP CARE

Regional Prepaid Inpatient Health Plan (PIHP) Resources should be provided to Eligible Individuals by the pharmacist utilizing this standing order. The resource pamphlet will list mental health and substance abuse services for people in that PIHP Region.

VIII. REPORTING OF NALOXONE DISPENSING

Monitoring naloxone dispensing: Pharmacists dispensing naloxone under this standing order are required to provide quarterly reports to the Pharmacy Naloxone Registration site email MDHHS-Naloxoneorder@michigan.gov, on a quarterly basis. The report shall contain the total number of naloxone doses dispensed under this standing order under the delegating provider's NPI, along with the total of naloxone doses dispensed in total by the pharmacy for the time period, the number of each type of formulation dispensed, and the pharmacy name and license number. No protected health information specific to any Eligible Individuals may be included in the report.

IX. REVIEW

This standing order will automatically expire on the date that the physician whose signature appears below has ceased to function in the capacity of CME, or until otherwise provided by law, whichever occurs first. MDHHS will distribute a notice to all licensed pharmacies if the standing order is altered or revoked.

Dates of Amendments: May 22, 2018, January 25, 2019, April 28, 2019, October 1, 2021

October 19, 2021, June 2, 2023

THIS PAGE INTENTIONALLY LEFT BLANK

ADDENDUM - MICHIGAN STATEWIDE NALOXONE STANDING ORDER

Revised June 2, 2023

SAMPLE – UNSIGNED STANDING ORDER

The Chief Medical Executive does not provide prior authorizations under this standing order. Persons, pharmacists and insurance companies should work directly with the individuals primary care provider to obtain any prior authorization.

This standing order issued by The Chief Medical Executive, effective on the date below, authorizes all FDA-approved formulations of Naloxone to be dispensed by a pharmacist or community-based organization, and to maintain and/or administer naloxone, syringes, and other components of Naloxone Rescue Kits for the purpose of assembling and distributing kits to ELIGIBLE INDIVIDUALS that may be in a position to assist an individual suffering an opioid- related overdose.

FDA -Approved Nasal Narcan Dispensing Kit must contain:

- A pre-filled, ready-to-use dose of Narcan Nasal Spray.
- A guide of opioid overdose symptoms and assembly instructions.

FDA- approved Nasal Kloxxado Dispensing Kit must contain:

- A pre-filled, ready-to-use dose of Kloxxado Nasal Spray, and
- A guide of opioid overdose symptoms and assembly instructions.

FDA- Approved Intramuscular Naloxone Rescue Kits (syringe) must contain:

- A 1 mL (0.4 mg/mL) prefilled syringe or 2 mL (0.4 mg/mL or 1 mg/mL) pre-filled syringe or single dose vial (0.4 mg/mL) with syringe,
- Intramuscular needle, and
- A quick guide of opioid overdose symptoms and assembly instructions.

SIGNATURES:

Natasha Bagdasarian, MD, MPH, FIDSA
Chief Medical Executive



June 2, 2023

Date Signed/Effective Date

SIGNATURE

By signing this Naloxone Standing Order, the Pharmacy Manager of Record attests that they have read and understand both the State of Michigan Naloxone Standing Order and the reference materials provided with the Standing Order (also available online at: <http://www.michigan.gov/bhrecovery>)

Pharmacy Manager of Record's Signature **Date**

Pharmacy Manager of Record's Name and License No. (print legibly)

Pharmacy Name and Store Number

Pharmacy Address |